Ellis Ronald J. Jr.
Known title: Chief Strategy OfficerCIK: 0001790670
Associated companies
Transaction History
| PCRX | ▼ Sell | Open Market | 1,162 | $44K | 6/7/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,114 | $43K | 6/6/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,162 | $44K | 6/7/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,114 | $43K | 6/6/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.